Dyne Therapeutics
DYN25.9001.05% ( +0.270 )
Dyne Therapeutics (DYN)
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the Un...
- Open
- 25.420
- High
- 26.260
- Low
- 25.180
- Prev. Close
- 25.630
- Volume
- 2.33M
- Turnover
- 60.25M
- Avg Price
- 25.805
- Bid/Ask Ratio
- --
- Amplitude
- 4.21%
- 52wk High
- 26.260
- Volume Ratio
- 0.49
- Turnover Ratio
- 1.50%
Dyne Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 23, 2026Price forecast
$39.3351.87%
Forecast & RatingStrong buy
17analysts
- Strong buy76.47%
- Buy17.65%
- Hold5.88%
- Sell0.00%
- Strong sell0.00%
News
- Unusual Whales · 14 hours ago
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
- rttnews · 17 hours ago
Biotech Stocks At 52-Week Highs - LH Rises With Genetic Testing Launch, DYN, SNDA, SLN, AMLX,
- StockTitan · Jul 24 at 07:05 AM
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | DYN Stock News
- PUBT · Jul 23 at 03:29 PM
Dyne Therapeutics closes upsized public offering of 21,045,000 shares at $20.5 each
- Unusual Whales · Jul 23 at 03:08 PM
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
- Tip Ranks · Jul 22 at 04:51 PM
Dyne Therapeutics Upsized Equity Offering Strengthens Cash Runway
